All Stories

  1. Assessing measurement bias in substance withdrawal symptoms attributable to childhood adversity and genetic liability
  2. Investigating genetic overlap of multidimensional pain and suicidal behaviors in >2 million individuals
  3. Education shares distinct genetic influences with substance use and disorder
  4. Phenome-wide analysis of genetically imputed neuroimaging phenotypes reveals associations with psychiatric traits in a multi-ancestry cohort
  5. Racial and ethnic disparities in buprenorphine retention and treatment outcome in a longitudinal cohort of U.S. veterans with opioid use disorder
  6. Whole-exome sequencing study of opioid dependence offers novel insights into the contributions of exome variants
  7. The genetics of cannabis lifetime use
  8. Multi-ancestry Genome-wide Association Study of Inpatient Opioid Dosing Following Knee or Hip Arthroplasty
  9. Polygenic risk and childhood adversity as moderators of drug and alcohol withdrawal symptoms
  10. Multi-ancestry Genome-wide Association Study of Inpatient Opioid Dosing Following Knee or Hip Arthroplasty
  11. Disaggregating the Genetic Overlap Between Educational Attainment and Substance Use Phenotypes
  12. Moderation of treatment outcomes by polygenic risk for alcohol‐related traits in placebo‐controlled trials of topiramate
  13. Multi‐ancestry genome‐wide association study of topiramate's effects on heavy alcohol use
  14. A single-cell genomic atlas for the effects of chronic ethanol exposure in the mouse dorsal striatum
  15. Gene discovery and pleiotropic architecture of chronic pain in a genome-wide association study of >1.2 million individuals
  16. Social network alcohol use is associated with individual‐level alcohol use among Black sexually minoritized men and gender‐expansive people: Findings from the Neighborhoods and Networks (N2) cohort study
  17. Communication-efficient federated learning of temporal effects on opioid use disorder with data from distributed research networks
  18. Associations of Childhood Adversity and Polygenic Scores with Substance Use Initiation and Disorder Severity
  19. Associations of Childhood Adversity and Polygenic Scores with Substance Use Initiation and Disorder Severity – ERRATUM
  20. Integrating HiTOP and RDoC frameworks Part I: Genetic architecture of externalizing and internalizing psychopathology
  21. Integrating HiTOP and RDoC frameworks part II: shared and distinct biological mechanisms of externalizing and internalizing psychopathology
  22. A Mendelian randomization study of alcohol use and cardiometabolic disease risk in a multi‐ancestry population from the Million Veteran Program
  23. Addressing Disparities in Alcohol Use Disorder Treatment: A Call to Action
  24. Considerations for the application of polygenic scores to clinical care of individuals with substance use disorders
  25. Association patterns of antisocial personality disorder across substance use disorders
  26. A genome-wide investigation into the underlying genetic architecture of personality traits and overlap with psychopathology
  27. Application of polygenic scores to a deeply phenotyped sample enriched for substance use disorders reveals extensive pleiotropy with psychiatric and somatic traits
  28. Identifying neurofunctional domains across substance use disorders
  29. Gene × environment effects and mediation involving adverse childhood events, mood and anxiety disorders, and substance dependence
  30. Combining Transdiagnostic and Disorder-Level GWAS Enhances Precision of Psychiatric Genetic Risk Profiles in a Multi-Ancestry Sample
  31. Welcoming ACER's new Editor
  32. Integrating HiTOP and RDoC Frameworks Part I: Genetic Architecture of Externalizing and Internalizing Psychopathology
  33. A Multivariate Genome-Wide Association Study Reveals Neural Correlates and Common Biological Mechanisms of Psychopathology Spectra
  34. Genetic and non-genetic predictors of risk for opioid dependence
  35. Reductions in WHO risk drinking levels correlate with alcohol craving among individuals with alcohol use disorder
  36. Prevalence and correlates of DSM-5 opioid withdrawal syndrome in U.S. adults with non-medical use of prescription opioids: results from a national sample
  37. Comparing the Psychometric Properties of Reward and Relief Drinking Measures
  38. Adverse Childhood Events, Mood and Anxiety Disorders, and Substance Dependence: Gene x Environment Effects and Moderated Mediation
  39. Adverse Childhood Events, Mood and Anxiety Disorders, and Substance Dependence: Gene X Environment Effects and Moderated Mediation
  40. Demographic differences in the cascade of care for unhealthy alcohol use: A cross‐sectional analysis of data from the 2015–2019 National Survey on Drug Use and Health
  41. Medications for treating alcohol use disorder: A narrative review
  42. Genetic Underpinnings of the Transition From Alcohol Consumption to Alcohol Use Disorder: Shared and Unique Genetic Architectures in a Cross-Ancestry Sample
  43. Identifying genetic loci and phenomic associations of substance use traits: A multi‐trait analysis of GWAS (MTAG) study
  44. Metabolic Profiles Associated with Opioid Use and Opioid Use Disorder: a Narrative Review of the Literature
  45. Does polygenic risk for substance‐related traits predict ages of onset and progression of symptoms?
  46. Multi-trait genome-wide association analyses leveraging alcohol use disorder findings identify novel loci for smoking behaviors in the Million Veteran Program
  47. Racial and Ethnic Bias in the Diagnosis of Alcohol Use Disorder in Veterans
  48. The genetic architecture of pain intensity in a sample of 598,339 U.S. veterans
  49. Effects of topiramate therapy on serum bicarbonate concentration in a sample of 10,279 veterans
  50. An intensive longitudinal examination of topiramate treatment for alcohol use disorder: a secondary analysis of data from a randomized controlled trial
  51. Announcing a name change for ACER
  52. Polygenic Risk for Substance-Related Traits Predicts Substance Use Onset and Progression: Sex and Population Group Differences
  53. A randomized, double‐blind, placebo‐controlled, pharmacogenetic study of ondansetron for treating alcohol use disorder
  54. Integrating human brain proteomic data with genome-wide association study findings identifies novel brain proteins in substance use traits
  55. Association of topiramate prescribed for any indication with reduced alcohol consumption in electronic health record data
  56. Using 18F-NOS PET Imaging to Measure Pulmonary Inflammation in Electronic and Combustible Cigarette Users: A Pilot Study
  57. Association of Topiramate Prescribed for any Indication with Reduced Alcohol Consumption in Electronic Health Record Data
  58. Is it time to rethink low‐risk drinking guidelines?
  59. Associations between alcohol consumption and gray and white matter volumes in the UK Biobank
  60. Alcohol withdrawal in past‐year drinkers with unhealthy alcohol use: Prevalence, characteristics, and correlates in a national epidemiologic survey
  61. Using phenotype risk scores to enhance gene discovery for generalized anxiety disorder and posttraumatic stress disorder
  62. Within‐ and between‐person effects of naltrexone on the subjective response to alcohol and craving: A daily diary investigation
  63. Genome-wide meta-analysis of alcohol use disorder in East Asians
  64. Post‐treatment effects of topiramate on alcohol‐related outcomes: A combined analysis of two placebo‐controlled trials
  65. Identifying and Reducing Bias in Genome-Wide Association Studies of Alcohol-Related Traits
  66. Placebo-controlled trial of bupropion for smoking cessation in pregnant women
  67. Genetic liability for substance use associated with medical comorbidities in electronic health records of African‐ and European‐ancestry individuals
  68. Analysis of genetic and clinical factors associated with buprenorphine response
  69. Combined analysis of the moderating effect of a GRIK1 polymorphism on the effects of topiramate for treating alcohol use disorder
  70. Comorbid-phenome prediction and phenotype risk scores enhance gene discovery for generalized anxiety disorder and posttraumatic stress disorder
  71. World Health Organization risk drinking levels as a treatment outcome measure in topiramate trials
  72. Genome-wide association study of stimulant dependence
  73. The impact of removing former drinkers from genome‐wide association studies of AUDIT‐C
  74. Accuracy of Consumer‐marketed smartphone‐paired alcohol breath testing devices: A laboratory validation study
  75. Correction to: Prospective randomized pharmacogenetic study of topiramate for treating alcohol use disorder
  76. The phenomics and genetics of addictive and affective comorbidity in opioid use disorder
  77. Reward drinking and naltrexone treatment response among young adult heavy drinkers
  78. Prospective randomized pharmacogenetic study of topiramate for treating alcohol use disorder
  79. Effects of topiramate on neural responses to alcohol cues in treatment-seeking individuals with alcohol use disorder: preliminary findings from a randomized, placebo-controlled trial
  80. Epigenomic Profiles of African-American Transthyretin Val122Ile Carriers Reveals Putatively Dysregulated Amyloid Mechanisms
  81. Genetic underpinnings of risky behaviour relate to altered neuroanatomy
  82. Multi-environment gene interactions linked to the interplay between polysubstance dependence and suicidality
  83. A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder
  84. Pregnant Smokers Receiving Opioid Agonist Therapy Have an Elevated Nicotine Metabolite Ratio: A Replication Study
  85. World Health Organization Risk Drinking Level Reductions Are Associated with Improved Functioning and Are Sustained Among Patients with Mild, Moderate, and Severe Alcohol Dependence in Clinical Trials in the United States and United Kingdom
  86. An analysis of the effect of mu-opioid receptor gene (OPRM1) promoter region DNA methylation on the response of naltrexone treatment of alcohol dependence
  87. Genome-Wide Association Study of Opioid Cessation
  88. Author Correction: Genomewide Study of Epigenetic Biomarkers of Opioid Dependence in European- American Women
  89. Genomewide Gene-by-Sex Interaction Scans Identify ADGRV1 for Sex Differences in Opioid Dependent African Americans
  90. A regulatory variant of CHRM3 is associated with cannabis-induced hallucinations in European Americans
  91. Author Correction: Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations
  92. A meta‐analysis of the efficacy of gabapentin for treating alcohol use disorder
  93. Author Correction: Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations
  94. Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations
  95. Reduction in non-abstinent WHO drinking risk levels and depression/anxiety disorders: 3-year follow-up results in the US general population
  96. Genomewide Study of Epigenetic Biomarkers of Opioid Dependence in European- American Women
  97. Alcohol-responsive genes identified in human iPSC-derived neural cultures
  98. GWAS and network analysis of co-occurring nicotine and alcohol dependence identifies significantly associated alleles and network
  99. Genome-wide association study identifies glutamate ionotropic receptor GRIA4 as a risk gene for comorbid nicotine dependence and major depression